依达拉奉治疗急性心肌梗塞的疗效观察  

Therapeutic effect of edaravone on acute myocardial infarction

作　　者：张利华[1] 刘军[1] 李波[1] 杨欣国[1] 

机构地区：[1]第四军医大学唐都医院心内科,陕西西安710038

出　　处：《心血管康复医学杂志》2009年第4期381-382,共2页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:观察依达拉奉治疗急性心肌梗塞(AMI)的疗效。方法:60例发病48h内行溶栓或经皮冠状动脉介入治疗(PCI)后的心肌梗塞患者被随机分为对照组(32例)、依达拉奉组(28例),治疗2～3周后比较疗效。结果:与对照组相比,依达拉奉组患者左室射血分数(LVEF)明显升高[51.9±4.99)%:(55.31±5.36)%,P<0.05],住院期间恶性心律失常发生率明显降低(25.9%:13.3%,P<0.05),但两组患者住院期间总体病死率无明显差异(P>0.05)。结论:依达拉奉作为一种新型氧自由基清除剂,治疗急性心肌梗塞有明显的疗效。Objective： To observe the efficacy of edaravone on acute myocardial infarction （AMI）. Methods： Sixty AMI patients in 48 h and after treatment of thrombolysis or PCI were randomly divided into 2 groups： Routine therapy control group （n= 30） and edaravone group （n= 28）, the efficacy was assessed between two groups 2-3 weeks after treatment. Results： Compared with control group, the level of LVEF significantly increased [51.9 ± 4.99）% vs. （55.31 ± 5.36）%, P〈0.05], and the incidence of malignant arrhythmia decreased dramatically （25.9% vs. 13.3% , P〈0.05）, but there was no significant difference in fatality rate between two groups （P〉0.05）. Conclusion： As a new hydro--free radical scavenger, edaravone has obvious effects on acute myocardial infarction.

关 键 词：依达拉奉 心肌梗塞 再灌注损伤 

分 类 号：R542.22[医药卫生—心血管疾病]